DOCSLIB.ORG

Mismatched Living Donor Kidney Transplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mismatched Living Donor Kidney Transplantation IMMUNOHEMATOLOGY Impact of donor ABH-secretor status in ABO-mismatched living donor kidney transplantation Beatrice Drexler,1,2 Andreas Holbro,1,2 Joerg Sigle,3 Christoph Gassner,4 Beat M. Frey,4 Stefan Schaub,5 Patrizia Amico,5 Alexandra Plattner,1,2 Laura Infanti,1,2 Thomas Menter,6 Michael Jorg€ Mihatsch,6 Martin Stern,7 Andreas Buser,1,2 and Michael Dickenmann5 BO-mismatched living donor kidney transplan- BACKGROUND: The ABO blood group is a major tation is increasingly performed for patients determinant in living donor kidney transplantation since with end-stage kidney disease1 and was dem- AB antigens are expressed on renal tissue. Little onstrated to improve survival.2 Initial attempts attention has been directed to the ABH-secretor status of A of transplanting across the ABO blood group barrier were the donor kidney. As renal tissue is capable of secreting associated with high rates of early graft loss due to soluble ABH antigens in secretors, we examined the antibody-mediated rejection (AMR).3 In recent years, influence of the ABH-secretor status of kidney donors on progress in pretransplant antibody removal and immuno- outcome in ABO-mismatched living donor kidney suppression has markedly improved outcome after transplantation. ABO-mismatched living donor kidney transplantation4 STUDY DESIGN AND METHODS: We retrospectively analyzed all patients who underwent and therefore has become a standard procedure in many ABO-mismatched kidney transplantation at the University centers. Hospital Basel from September 2005 to October 2013. The ABH-secretor status was determined in all donors by molecular genetic analysis. RESULTS: Of all 55 patients who received transplants, ABBREVIATIONS: AMR 5 antibody-mediated rejection; we excluded all patients with donor-specific antibodies DSA 5 donor-specific anti-HLA; FUT2 5a1,2-l- (n 5 4). Forty-one donors were secretors (78%) and 11 fucosyltransferase 2; GFR 5 glomerular filtration rate; IA 5 were nonsecretors (22%). Recipients of ABH-secretor immunoadsorption; IQR 5 interquartile range. donor organs showed a significantly higher glomerular From the 1Department of Haematology, University Hospital filtration rate throughout the first 6 months Basel; and the 2Blood Transfusion Centre, Swiss Red Cross, posttransplant, whereas no significant influence on Basel, Switzerland; the 3Blood Transfusion Centre, Swiss Red posttransplant anti-A/B titers was found. Regression Cross, Aarau, Switzerland; the 4Blood Transfusion Service, analysis revealed a significant impact on humoral Swiss Red Cross, Zurich, Switzerland; and the 5Clinic for rejection, whereas not on vascular or interstitial rejection Transplant Immunology and Nephrology, the 6Institute for in protocol kidney biopsies. Pathology, and the 7Immunotherapy Laboratory, Department of CONCLUSION: The donor ABH-secretor status may Biomedicine, University Hospital Basel, Basel, Switzerland. have an influence on early posttransplant renal function Address correspondence to: Beatrice Drexler, University in patients undergoing ABO-mismatched living donor Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland; kidney transplantation. Further prospective studies with e-mail: [email protected]. long-term follow-up are needed to elucidate involved AB and MD shared last authorship. pathomechanisms. The study was supported by a research grant from the regional Blood Transfusion Center Basel, Swiss Red Cross, Switzerland. Received for publication August 14, 2015; revision received March 22, 2016; and accepted April 25, 2016. doi:10.1111/trf.13711 VC 2016 AABB TRANSFUSION 2016;56;2355–2361 Volume 56, September 2016 TRANSFUSION 2355 DREXLER ET AL. However, the mechanisms of transplant accommoda- (PCR) using sequence-specific priming technology in two tion and the early immunologic response in ABO- independent reactions. Heterozygous individuals would mismatched kidney transplantation is poorly understood so give positive amplification in both reactions, homozygous far. After pretransplant antibody removal by immunoad- individuals in one reaction only. Primers for the wild-type sorption and immunosuppressive treatment, isoagglutinin allele (428G) were FUT2-all1523R (CCGGCTCCCGTTCA titers tend to stay low in the posttransplant period.5 How- CCTG-30) and FUT2-Se1428G-F (CCGGCTACCCCTGCTC ever, the exact mechanisms for this phenomenon remains GTG-30), and FUT2-all1523R and FUT-se1428A-F (ACC unknown and little attention has been directed to the ABH- GGCTACCCCTGCTCGTA-30) for the mutant allele (428A), secretor status of the donor kidney. The term ABH secretor respectively. Concentrations of the primers in the final refers to the ability to secrete soluble ABH blood group sub- reaction volume were 200 nmol/L, those of the control 6 stances into body fluids, such as plasma or saliva. For primers (GH1 1 96-F, TGCCTTCCCAACCATTCCCTTA-30; example, group A secretors will secrete A substance. ABH and GH1 1 274-R, CCACTCACGGATTTCTGTTGTGTTTC-30, secretion is controlled by two inherited alleles (Se and se), resulting in a 434-bp PCR product) 90 nmol/L. All primers where Se is dominant and se is recessive. Approximately were provided by an oligonucleotide synthesizing service 80% of individuals are secretors (SeSe or Sese). The secretor (Microsynth). Beside primers, the final PCR–sequence- gene (Se) encodes for the enzyme a1,2-L-fucosyltransferase specific priming reaction composition and cycling parame- 2 (FUT2) that converts the H-precursor substance in tissues ters were as described previously for KEL*01/KEL*02 to H-substance, which can be further converted to A- and/ genotyping.11 or B-substance according to the individual’s personal blood group.7 Interestingly, renal tissue is also able to secrete solu- ble A and B blood group substance according to their ABH- Patient preparation and desensitization protocol secretor status.8-10 In consequence, we hypothesized that All patients were prepared and desensitized as previously the secretion of ABH antigens by donor kidneys is capable described.12 In short, basic immunosuppressive therapy of neutralizing circulating anti-A and/or anti-B of the recipi- including tacrolimus (0.1 mg/kg body weight twice daily), ent in vivo and therefore contributes to the transplant mycophenolate mofetil (1000 mg twice daily, 500 mg twice accommodation after ABO-mismatched kidney transplan- dailyifbodyweightwas< 50 kg), and prednisone (30 mg tation. In this respect, the objective of this study was to once daily) was started 2 weeks before transplantation. A investigate the influence of thedonorABH-secretorstatus single dose of rituximab (375 mg/m2) was given 4 weeks on outcome in ABO-mismatched living donor kidney before transplantation in an outpatient setting. Selective transplantation. blood group antibody removal by immunoadsorption (IA) was performed pretransplant with a low-molecular carbo- MATERIALS AND METHODS hydrate column containing A and/or B blood group anti- gens linked to a Sepharose matrix (Glycosorb, Glycorex Study design and population Transplantation). IA was performed daily until the isoagglu- We retrospectively analyzed all patients who underwent tinin titers were 8 or less. The transplantation was then car- major ABO-mismatched kidney transplantation at the ried out the following day. If one of the two titers University Hospital Basel from September 2005 to October remained higher than 8, additional IA was mandatory until 2013. Patients with donor-specific anti-HLA (DSA) were the target titer was achieved. With each session, two excluded. Patient, donor, and transplant characteristics plasma volumes, calculated with the formula of Kaplan13 were collected by chart review and through the electronic were processed. Additional 20 mg of intravenous (IV) basi- database of our institution. Donor-recipient pairs were liximab was administered on Days 0 and 4. Target tacroli- classified according to the ABH-secretor status of the mus trough levels were 10 to 12 ng/mL from Day 214 until donor. The study was approved by the local ethics Day 31, 8 to 10 ng/mL from Day 32 to Day 90, and 6 to 8 committee. ng/mL from Day 91 to Day 365 and 4 to 6 ng/mL there- after. Target mycophenolate mofetil trough level was more Molecular genetic analysis of secretor status than 2 mg/mL. Steroids (IV methylprednisolone and Pretransplant venous blood samples from the kidney prednisone orally) were tapered (500 mg IV on Day 0, donors were collected in tubes containing EDTA. Periph- 250 mg IV on Day 1, 100 mg IV on Day 2, 50 mg from eral blood mononuclear cells were isolated with the Day 3 to Day 6, and 0.5 mg/kg body weight from Day 7 Ficoll-Paque method. Samples were frozen at 2808Cfor with a reduction by 5 mg every 2 weeks until 15 mg/day later analysis. Genomic DNA was isolated with the use of andthenby2.5mgevery2weeksuntilamaintenance a DNA isolation kit (MagnaPure LC, Roche Diagnostics). dose of 0.1 mg/kg body weight). All complications of Wild-type (Se, 428G) and mutant (se, 428A) alleles of pretransplant preparation were prospectively recorded FUT2 gene were detected by polymerase chain reaction at each clinical visit. 2356 TRANSFUSION Volume 56, September 2016 ABH-SECRETOR IN KIDNEY TRANSPLANTATION Isoagglutinin titers test. A multivariate regression analysis was generated to Serologic blood group typing and antibody screening was evaluate the impact of recipient sex, blood group, initial performed by gel test (Gel Test ID-system, Bio-Rad Labo- titer, plasma transfusion, and secretor status on the risk of ratories DiaMed GmbH). The isoagglutinin
Load more

Recommended publications
  • Study of Blood Group (ABO and RH) Association and Secretor Status of ABH Substances in Patients with Systemic Lupus Erythematosus
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 18, Issue 5 Ser. 12 (May. 2019), PP 31-35 www.iosrjournals.org Study of Blood Group (ABO and RH) Association and Secretor Status of ABH Substances in Patients with Systemic Lupus Erythematosus Dr. Tashi Paleng1, Dr. A. Barindra Sharma2, Dr.Santa Naorem3, Dr. Laikangbam Dayalaxmi4, Dr. Eric Hilton Wanniang5, Dr. Eswara Moorthy G6 1Postgraduate trainee, 2Professor & Head, 3Professor, 4Senoir Resident, 5Postgraduate trainee, 6Postgraduate trainee 1,2,4,5,6Department of Transfusion Medicine, 3Department of Medicine, Regional Institute of Medical Sciences, Imphal-795004, Manipur, India Corresponding Author: Dr. Tashi Paleng Abstract: Individuals who secrete their blood group antigens in the body fluids are called secretors and individuals who do not secrete are called non-secretors. Non-secretors of blood group antigens have been found to be associated with many infectious and autoimmune diseases by many previous studies. The aims of our study were to find out any association between ABO blood group, RhD blood group and secretor status of ABH substances with the patients of Systemic Lupus Erythematosus. This Case Control study was carried out in the Department of Transfusion Medicine in collaboration with the Department of Medicine, Regional Institute of Medical Sciences, Imphal Manipur from September 2016 to August 2018. 75 confirmed SLE patients attending Rheumatology OPD, Department of Medicine and 75 healthy sex matched voluntary blood donors attending blood bank, Department of Tranfusion Medicine have been enrolled in the study. Their blood were typed for ABO and RhD groups using conventional tube technique and saliva were tested for secretor and non-secretor status using heamagglutination inhibition test.
    [Show full text]
  • Transfusion in a Rare Case of Para-Bombay Phenotype
    TRANSFUSION IN A RARE CASE OF PARA-BOMBAY PHENOTYPE Charlotte Engström1, Stefan Meyer2, Young-Lan Song1, Adriana Komarek1, Alix O’Meara3, Claudia Papet3, Kathrin Neuenschwander2, Christoph Gassner2, Beat M. Frey1 1 Immunohematology, Blood Transfusion Service Zurich, Swiss Red Cross, Switzerland. 2 Molecular Diagnostics & Research, Blood Transfusion Service Zurich, Swiss Red Cross , Switzerland. 3 Hematology/Oncology, Spital Limmattal, Schlieren, Switzerland. Background Results Individuals with Bombay phenotype are characterized by the The routine anti-A, -B and -A/B failed to detect the respective absence of ABH blood group antigens both on the surface of antigens and, most notably, no H-antigen was traceable. The red blood cells (RBCs) and in secretions resulting from RBCs showed only weak agglutination with the potent anti-A/B silenced mutations in FUT1 (h/h) and FUT2 (se/se) genes, serum (Grifols). Only anti-H, but no anti-A or anti-B, was respectively. In contrast, para-Bombay phenotype retains identified in the serum. Initial ABO genotyping by sequence- some H antigen on RBCs either induced from a weakly active specific priming (PCR-SSP) resulted in AB genotype. In order (H+weak/H+weak) or completely silenced FUT1 gene (h/h). to confirm serological H-deficient phenotype a more detailed The latter is mandatory linked with an active FUT2 gene analysis was performed including sequencing of FUT1 and (Se/Se or Se/se) enabling synthesis of ABH-antigens in FUT2 which revealed an active secretor status (Se/Se) but secretions which may be adsorbed from the plasma onto homozygosity for the FUT1*01W.09 allele (c.658C>T, RBCs surface (1, 2).
    [Show full text]
  • The Incidence of Spontaneous Abortion in Mothers with Blood Group O Compared with Other Blood Types
    IJMCM Meta analysis Spring 2012, Vol 1, No 2 The incidence of spontaneous abortion in mothers with blood group O compared with other blood types ∗ Mohammad Hassanzadeh-Nazarabadi 1∗∗, Sahar Shekouhi 1, Najmeh Seif 1 Faculty of Medicince, Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran Although ABO incompatibility between mother and fetus has long been suspected as cause of spontaneous abortion in man, its precise contribution has not been completely resolved. In spite of reports in which the incompatible mating was recognized to be a cause of habitual abortion, and which eventually results in infertility or a reduction in the number of living children compared with the number in compatible matings, such effects were not observed in other studies. The aim of this review article was to show some evidence of relationship between ABO incompatibility and spontaneous abortion. Key words: spontaneous abortion, ABO blood group, incompatibility In 1900 Karl Landsteiner reported a series of discovered, attention was directed toward the tests, which identified the ABO blood group system. possibility of harmful effects when mother and This is the only blood group in which antibodies are fetus have different blood groups. As early as 1905 constantly, predictably, and naturally present in the A. Dienst suggested that toxemia of pregnancy serum of people who lack the antigen. ABO might be due to the transfusion of ABO- compatibility between mother and fetus is crucial (1). incompatible fetal blood into the mother. This was not substantiated, and the problem of ABO Downloaded from ijmcmed.org at 17:08 +0330 on Saturday September 25th 2021 Abortion interaction between mother and fetus was largely Spontaneous abortion also known as overshadowed by the more dramatic effects of Rh miscarriage, refers to a pregnancy that ends incompatibility leading to Rh hemolytic disease.
    [Show full text]
  • An Update on the Lewis Blood Group System
    B LOOD G ROUP R EVIEW An update on the Lewis blood group system M.R. Combs This update of the Lewis blood group system (Combs MR. Lewis chills, severe back pain, hemoglobinuria, and increased levels blood group system review. Immunohematology 2009;25:112–8) of bilirubin, alanine transaminase, and serum creatinine. A describes new information on the clinical significance of Lewis monocyte monolayer assay, testing the patient’s serum with antigens regarding susceptibility of individuals to certain diseases and the possible role of bacteria in Lewis expression. This update the Le(a+) RBCs causing the reaction, was positive also describes recently reported examples of Lewis antibodies A case report in 2015 of a possible HTR due to anti-Lea causing hemolytic transfusion reactions. No new antigens have was reported in a pregnant patient with sickle cell disease with been identified in the International Society of Blood Transfusion a 10 system 7, leaving the antigen count to stand at six: Lea, Leb, LebH, a 37°C gel-reactive anti-Le . The crossmatch was compatible ALeb, BLeb, and Leab. Immunohematology 2019;35:65–66. using prewarmed plasma neutralized with Lewis substance. During transfusion, the patient experienced significant Key Words: Lewis, fucosyltransferases, antigen, antibody dyspnea, hypotension, and hemoglobinuria. Indirect bilirubin and lactate dehydrogenase tests were elevated. The direct Lewis Antigens antiglobulin test on the post-transfusion sample was negative, indicating the possibility that all incompatible RBCs were Lewis antigen fucosyltransferases are encoded by the cleared. FUT3 gene located on chromosome 19p13.3.1 The presence or A case of an HTR due to anti-Leb, also in 2015, was absence of Lewis antigens in an individual can be associated reported.11 A pretransfusion sample from a 30-year-old with the individual’s susceptibility to certain diseases and African-American woman showed a negative antibody infections.
    [Show full text]
  • Secretor Status, Fucosyltransferase 2 (Fut2) Gene Polymorphisms and Susceptibility to Hiv Infections Among Female Sex Workers in Nairobi, Kenya
    SECRETOR STATUS, FUCOSYLTRANSFERASE 2 (FUT2) GENE POLYMORPHISMS AND SUSCEPTIBILITY TO HIV INFECTIONS AMONG FEMALE SEX WORKERS IN NAIROBI, KENYA Nadia Musimbi Chanzu W80/83581/2012 A Thesis Submitted in Fulfillment for the Degree of Doctor of Philosophy (Ph.D) in the University of Nairobi Institute of Tropical and Infectious Diseases University of Nairobi 2014 DECLARATION This Thesis is my original work and has not been presented for a degree in any other University. Nadia Musimbi Chanzu Signed: ………………………………………………… This Thesis has been presented with our approval as University Supervisors: Prof. Walter Mwanda, MBChB., MD. Signed: …………………………………………… Date: ……………………………………………… Prof. Omu Anzala, MBChB, PhD. Signed: …………………………………………… Date: ……………………………………………… Dr. Julius Oyugi, MSc. Ph.D Signed: …………………………………………… Date: ……………………………………………… ii DEDICATION This Thesis is dedicated to my parents, Yusuf Chanzu and Jamila Chanzu, my siblings, Abdalla, Issa, and Zahra. Thank you for the confidence you have always had in me. Thank you for your tremendous encouragement, support and prayers. I also dedicate this book to my late grandfather Abdalla Baraka Chanzu and my late great grandfather Baraka Lwoya Chanzu for their foresightedness which encouraged our family acquire high level quality education. iii ACKNOWLEDGEMENTS This work has had the support and goodwill of so many people that it is difficult to acknowledge each one of them individually, I would like to thank my entire family for their continued support. A special mention to my mother Jamila Chanzu, for always encouraging me to pursue my dreams, and teaching me that education was truly the key to success, her patience and kind heart. My father, Yusuf Chanzu for his continued support, mentorship and for teaching me that there is nothing impossible.
    [Show full text]
  • (FUT2) Non-Secretor Status and Blood Group B Are Associated With
    Downloaded from gut.bmj.com on September 29, 2014 - Published by group.bmj.com Gut Online First, published on July 15, 2014 as 10.1136/gutjnl-2014-306930 Pancreas ORIGINAL ARTICLE Fucosyltransferase 2 (FUT2) non-secretor status and blood group B are associated with elevated serum lipase activity in asymptomatic subjects, and an increased risk for chronic pancreatitis: a genetic association study Frank Ulrich Weiss,1 Claudia Schurmann,2,3 Annett Guenther,1 Florian Ernst,2 Alexander Teumer,2 Julia Mayerle,1 Peter Simon,1 Henry Völzke,4 Dörte Radke,4 Andreas Greinacher,5 Jens-Peter Kuehn,6 Martin Zenker,7 Uwe Völker,2 Georg Homuth,2 Markus M Lerch1 ▸ Additional material is ABSTRACT published online only. To view Objective Serum lipase activities above the threefold Significance of this study please visit the journal online (http://dx.doi.org/10.1136/ upper reference limit indicate acute pancreatitis. We gutjnl-2014-306930). investigated whether high lipase activity—within the reference range and in the absence of pancreatitis—are What is already known on this subject? For numbered affiliations see ▸ The definition of acute pancreatitis includes end of article. associated with genetic single nucleotide polymorphisms (SNP), and whether these identified SNPs are also characteristic clinical symptoms in combination Correspondence to associated with clinical pancreatitis. with elevated serum enzyme activities (amylase Professor Markus M Lerch, or lipase) above three times the upper Methods Genome-wide association studies (GWAS) on 1 Department of Medicine A, ‘ ’ ‘ reference limit. Elevated lipase levels below University Medicine Greifswald, phenotypes serum lipase activity and high serum lipase activity’ were conducted including 3966 German this cut-off are not considered diagnostic for Fleischmannstrasse 41, pancreatitis, and can be observed in a number 17475 Greifswald, Germany; volunteers from the population-based Study-of-Health-in- [email protected] of non-pancreatic conditions.
    [Show full text]
  • Impact of Recipient ABH Secretor Status on Outcome in Minor ABO-Incompatible Hematopoietic Stem Cell Transplantation
    TRANSPLANTATION AND CELLULAR ENGINEERING Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation Andreas Holbro,1,2 Martin Stern,1 Laura Infanti,1,2 Alix O’Meara,1 Beatrice Drexler,1 Beat M. Frey,3 Jean-Marie Tiercy,4 Jakob R. Passweg,1 Christoph Gassner,3 Andreas Buser,1,2 and Joerg-Peter Sigle2,5 llogeneic hematopoietic stem cell transplanta- BACKGROUND: The impact of ABO incompatibility on tion (HSCT) is a potentially curative treatment hematopoietic stem cell transplantation (HSCT) approach for different malignant and nonma- outcome is controversial. As ABH substances are lignant diseases.1 Several given factors such expressed on tissues and secreted in body fluids, they Aas patient age, comorbidities, donor type, and donor- could drive an immune response in minor ABO- recipient sex combinations have been shown to affect sur- incompatible HSCT. The aim of the study was to inves- vival and major outcomes after HSCT.2 Scoring systems tigate the prognostic role of the recipients’ ABH secretor integrate these pretransplant determinants into a global status. transplant risk assessment.3 STUDY DESIGN AND METHODS: Patients who under- ABO incompatibility is not considered an obstacle for went minor ABO-incompatible HSCT were included. HSCT and occurs in approximately 30% to 50% of trans- Secretor status was determined either serologically or plants.4 Different types of donor-recipient ABO incompat- by molecular genetics. ibilities exist and are classified as either major, minor, or RESULTS: Between March 1996 and June 2012, a bidirectional.5 In major ABO-incompatible HSCT the total of 176 patients received minor ABO-incompatible patient has preformed antibodies (i.e.
    [Show full text]
  • Questionable ABO Blood Grouping in the Setting of Solid Organ Transplantation-A Case Report and Possible Resolution Techniques
    Hematology & Transfusion International Journal Case Report Open Access Questionable ABO blood grouping in the setting of solid organ transplantation-a case report and possible resolution techniques Abstract Volume 4 Issue 1 - 2017 A 52 year-old male who was admitted to our hospital for a penetrating chest trauma, Hanan Gerges, Susan Nahirniak as per our policy, a massive hemorrhage protocol (MHP) was activated to expedite Department of Laboratory Medicine and Pathology, University laboratory testing results and provision of blood products. On arrival, no identity or of Alberta and Alberta Health Services, Canada age were known, so 2units of unmatched group O, Rh positive red cells were issued while preparing an unmatched MHP pack which usually contains 6units of group O, Correspondence: Hanan Gerges, Department of Laboratory Rh positive red cells, 2units of AB plasma +/- one unit of platelets. No specimen was Medicine and Pathology, 4B1.23 WMC University of Alberta submitted for type and screen as the patient was bleeding profusely from the chest Hospital, 8440-12 St. Edmonton, AB, T6G 2B7, Canada, Fax wound. Despite multiple requests, we continued to provide blood products and a sample 1(780)407-8599, Tel 1 (780)297-8420, was received only after transfusing 24packed red cells, 2units of plasma and 1unit of Email [email protected] pooled platelets. As expected, both forward and reverse grouping showed mixed field reactions and accordingly interpreted by policy as questionable ABO. Rh typing was Received: October 14, 2016 | Published: February 15, 2017 clearly positive. The patient continued to be supported during surgery with group O red cells and AB plasma.
    [Show full text]
  • Immunohematology Vol 21, #4
    D DDD D DDD D D D DDD D DDD D D ImmunohematologyD D D D JOURNALDD OF BLOOD GROUP SEROLOGYDD AND EDUCATION D D DDD D DDD D DDD D DDD D D D DDD D DDD D DDD D DDD D D D DDD D DDD D DDD D DDD D D D DDV OLUMED 21, NUMBER 4,D 2005 D D D Immunohematology JOURNAL OF BLOOD GROUP SEROLOGY AND EDUCATION VOLUME 21, NUMBER 4, 2005 CONTENTS 141 Review: the Rh blood group system: an historical calendar P. D . I SSITT 146 Reactivity of FDA-approved anti-D reagents with partial D red blood cells W. J. J UDD,M.MOULDS,AND G. SCHLANSER 149 Case report: immune anti-D stimulated by transfusion of fresh frozen plasma M. CONNOLLY,W.N.ERBER,AND D.E. GREY 152 Incidence of weak D in blood donors typed as D positive by the Olympus PK 7200 C.M. JENKINS, S.T. JOHNSON, D.B. BELLISSIMO,AND J.L. GOTTSCHALL 155 Review: the Rh blood group D antigen . dominant, diverse, and difficult C.M.WESTHOFF 164 COMMUNICATIONS Letters from the editors Ortho-Clinical Diagnostics sponsorship Thank you to contributors to the 2005 issues 166 168 Letters from the outgoing editor-in-chief Letter from the incoming editorial staff Thank you with special thanks to Delores Changing of the guard 169 IN MEMORIAM John Maxwell Bowman, MD; Professor Sir John V.Davies, MD;Tibor J.Greenwalt, MD; and Professor J.J.Van Loghem 174 176 177 ANNOUNCEMENTS UPCOMING MEETINGS ADVERTISEMENTS 180 INSTRUCTIONS FOR AUTHORS 181 INDEX — V OLUME 21, NOS.
    [Show full text]
  • Para-Bombay B Phenotype: a Rare ABH Blood Group Variant at Tertiary
    J Res Clin Med, 2021, 9: 21 doi: 10.34172/jrcm.2021.021 TUOMS https://jrcm.tbzmed.ac.ir P R E S S Case Report Para-Bombay B phenotype: a rare ABH blood group variant at tertiary care hospital, Gwalior India Dharmesh Chandra Sharma1* ID , Sunita Rai2, Sachin Singhal3, Prakriti Gupta4, Shailendra Sharma5 1Associate Blood Transfusion Officer (ABTO), Incharge, BCSU & Aphaeresis, Blood Bank Department of Pathology, G. R. Medical College, Gwalior, India 2Assistant Professor, Pathology G. R. Medical College, Gwalior, India 3Medical Officer G. R. Medical College, Gwalior, India 4Demonstrator, Department of Pathology G. R. Medical College, Gwalior, India 5Post Graduate Student, Department of Pathology G. R. Medical College, Gwalior, India Article info Abstract Article History: The H antigen is the precursor substance for A and B antigens formation on red blood cells of Received: 14 Feb. 2021 an individual, and its absence is termed as H deficient phenotype. The lack of H antigen on Accepted: 12 Apr. 2021 both red blood cell (RBCs) and secretions results in a classical Bombay phenotype with anti-H e-Published: 14 May 2021 antibodies in serum. If the H antigen is absent on RBCs and present in secretions and plasma, the resulting blood group is the Para-Bombay phenotype. Although, the H gene is genetically Keywords: absent in Para-Bombay (hh genotype), at least one Se (Secretor) gene is present. Para-Bombay or • H-antigen red blood cell (RBC) H negative secretor individuals may or may not have anti-H in their serum. • Para-Bombay In both cases, routine blood grouping is O.
    [Show full text]
  • Vel Blood Group System: a Review J.R
    Journal of Blood Group Serology and Molecular Genetics VOLUME 33, N UMBER 2, 2017 This issue of Immunohematology is supported by a contribution from Grifols Diagnostics Solutions, Inc. Dedicated to advancement and education in molecular and serologic immunohematology Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 33, Number 2, 2017 CONTENTS C ASE R EPO R T 51 Hematologic complications in a patient with Glycine soja polyagglutination following fresh frozen plasma transfusion R.P. Jajosky, L.O. Cook, E. Manaloor, J.F. Shikle, and R.J. Bollag R EVIEW 56 The Vel blood group system: a review J.R. Storry and T. Peyrard C ASE R EPO R T 60 Two cases of the variant RHD*DAU5 allele associated with maternal alloanti-D J.A. Duncan, S. Nahiriniak, R. Onell, and G. Clarke R EVIEW 64 The FORS awakens: review of a blood group system reborn A.K. Hult and M.L. Olsson C ASE R EPO R T 73 A suspected delayed hemolytic transfusion reaction mediated by anti-Joa R.P. Jajosky, W.C. Lumm, S.C. Wise, R.J. Bollag, and J.F. Shikle R EVIEW 76 Recognizing and resolving ABO discrepancies G.M. Meny B OOK R EVIEW 82 Bloody Brilliant: A History of Blood Groups and Blood Groupers S. Gerald Sandler 84 90 94 96 A NNOUN C EMENTS A DVE R TISEMENTS I NST R U C TIONS S U B S cr IPTION FO R A UTHO R S I NFO R M AT I O N E DITO R - IN -C HIEF E DITO R IAL B OA R D Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Geralyn M.
    [Show full text]
  • ISBT Science Series
    Science Series INTRODUCTION TO BLOOD TRANSFUSION: FROM DONOR TO RECIPIENT rstar @pikisupe Join the conversation on social media with the hashtag #IntrotoBloodTransfusion ISBT Science Series Volume 15 Supplement 1 December 2020 Special issue: Introduction to Blood Transfusion: From Donor to Recipient CONTENTS Volume 15, Number S1, December 2020 Special issue: Introduction to Blood Transfusion: From Donor to Recipient List of contributors………………………………………………………………………….. ............................................................................................. 1 First Edition • Introduction .......................................................................................................................................................................................... 3 Second Edition • Introduction .......................................................................................................................................................................................... 4 • Preface ................................................................................................................................................................................................... 5 Abbreviations ........................................................................................................................................................................................... 6 Glossary ......................................................................................................................................................................................
    [Show full text]